Literature DB >> 11968124

Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin.

Claire S Allardyce1, Paul J Dyson, Jonathan Coffey, Neil Johnson.   

Abstract

Cisplatin, cis-[PtCl2(NH3)2], is known to bind to human serum transferrin, but the binding site remains a matter of some debate. Electrospray ionisation mass spectrometry has been used to characterise the interaction of cisplatin with transferrin. The studies indicate that cisplatin initially docks with, and subsequently bonds covalently to, the hydroxyl functional group of threonine 457, with the loss of HCl affording a transferrin-O-PtCl(NH3)2 adduct. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11968124     DOI: 10.1002/rcm.662

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  17 in total

1.  Mass-spectrometric characterization of cisplatin binding sites on native and denatured ubiquitin.

Authors:  Ting Zhao; Fred L King
Journal:  J Biol Inorg Chem       Date:  2011-03-02       Impact factor: 3.358

2.  Insights into the binding sites of organometallic ruthenium anticancer compounds on peptides using ultra-high resolution mass spectrometry.

Authors:  Rebecca H Wills; Abraha Habtemariam; Andrea F Lopez-Clavijo; Mark P Barrow; Peter J Sadler; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2014-02-01       Impact factor: 3.109

3.  Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand.

Authors:  Alexander E Egger; Christian G Hartinger; Anna K Renfrew; Paul J Dyson
Journal:  J Biol Inorg Chem       Date:  2010-04-06       Impact factor: 3.358

4.  Use of top-down and bottom-up Fourier transform ion cyclotron resonance mass spectrometry for mapping calmodulin sites modified by platinum anticancer drugs.

Authors:  Huilin Li; Tzu-Yung Lin; Steve L Van Orden; Yao Zhao; Mark P Barrow; Ana M Pizarro; Yulin Qi; Peter J Sadler; Peter B O'Connor
Journal:  Anal Chem       Date:  2011-11-18       Impact factor: 6.986

5.  Proteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands: Further exceptions to the DNA paradigm.

Authors:  Leticia Cubo; Michael Groessl; Paul J Dyson; Adoración G Quiroga; Carmen Navarro-Ranninger; Angela Casini
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

6.  Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS.

Authors:  Michael Groessl; Mattia Terenghi; Angela Casini; Lisa Elviri; Ryszard Lobinski; Paul J Dyson
Journal:  J Anal At Spectrom       Date:  2010-03       Impact factor: 4.023

7.  Palladium(II) and platinum(II) bind strongly to an engineered blue copper protein.

Authors:  Matthew P McLaughlin; Thomas H Darrah; Patrick L Holland
Journal:  Inorg Chem       Date:  2011-10-25       Impact factor: 5.165

8.  Direct determination of the primary binding site of cisplatin on cytochrome C by mass spectrometry.

Authors:  Ting Zhao; Fred L King
Journal:  J Am Soc Mass Spectrom       Date:  2009-02-13       Impact factor: 3.109

9.  Identification of (eta6-arene)ruthenium(II) protein binding sites in E. coli cells by combined multidimensional liquid chromatography and ESI tandem mass spectrometry: specific binding of [(eta6-p-cymene)RuCl2 (DMSO)] to stress-regulated proteins and to helicases.

Authors:  Joanna Will; Andreas Kyas; William S Sheldrick; Dirk Wolters
Journal:  J Biol Inorg Chem       Date:  2007-05-22       Impact factor: 3.358

10.  Characterising the atypical 5'-CG DNA sequence specificity of 9-aminoacridine carboxamide Pt complexes.

Authors:  Hieronimus W Kava; Anne M Galea; Farhana Md Jamil; Yue Feng; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2014-05-15       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.